Skip to main content
. 2020 Dec 29;13(2):e11902. doi: 10.15252/emmm.201911902

Figure 7. T‐cell activation and PSA levels during treatment of three patients with castrate resistant, metastasized prostate carcinoma.

Figure 7

The IgGsc molecule was applied in escalating doses, with a starting dose of 20 µg (patient 1) or 40 µg (patients 2 and 3) to a maximum of ~ 2.6 mg, as indicated. PSA values were monitored and T‐cell activation was assessed by flow cytometry.